Septerna is a clinical-stage biotechnology company focused on drugs that target G protein-coupled receptors (GPCRs), a major class of cell-surface proteins. Its proprietary Native Complex Platform is designed to enable discovery of oral small-molecule candidates against GPCRs that have been difficult to drug. The pipeline spans areas such as endocrinology, immunology and inflammation for patients with significant unmet medical needs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0.2 | — | -21.5 | — |
| Q2 2025 | 0.1 | — | -24.8 | — |
| Q3 2025 | 21.5 | — | 8.2 | — |
| Q4 2025 | 24.1 | — | -10.7 | — |
| Q1 2026 | 26.5 | 12,011% | -8.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Hope Bancorp, Inc. (HOPE), FirstSun Capital Bancorp (FSUN), Fortrea Holdings Inc. (FTRE), S&T Bancorp, Inc. (STBA), Lindblad Expeditions Holdings, Inc. (LIND), Damora Therapeutics, Inc. (DMRA)